$0.98
3.40% yesterday
Nasdaq, Nov 25, 09:49 pm CET
ISIN
US55083R1041
Symbol
LYEL
Sector
Industry

Lyell Immunopharma Inc Stock price

$0.91
-0.01 1.52% 1M
-1.86 67.04% 6M
-1.03 52.94% YTD
-0.66 41.85% 1Y
-8.49 90.29% 3Y
-15.98 94.60% 5Y
-15.98 94.60% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.04 3.91%
ISIN
US55083R1041
Symbol
LYEL
Sector
Industry

Key metrics

Market capitalization $254.90m
Enterprise Value $-127.07m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.81
EV/Sales (TTM) EV/Sales -2,117.83
P/S ratio (TTM) P/S ratio 4,248.33
P/B ratio (TTM) P/B ratio 0.44
Revenue growth (TTM) Revenue growth -99.87%
Revenue (TTM) Revenue $60.00k
EBIT (operating result TTM) EBIT $-220.54m
Free Cash Flow (TTM) Free Cash Flow $-156.23m
Cash position $440.55m
EPS (TTM) EPS $-0.80
P/E forward negative
P/S forward 15,448.48
EV/Sales forward negative
Short interest 6.15%
Show more

Is Lyell Immunopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Lyell Immunopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Lyell Immunopharma Inc forecast:

2x Hold
67%
1x Sell
33%

Analyst Opinions

3 Analysts have issued a Lyell Immunopharma Inc forecast:

Hold
67%
Sell
33%

Financial data from Lyell Immunopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.06 0.06
100% 100%
100%
- Direct Costs 20 20
2% 2%
32,767%
-20 -20
167% 167%
-32,667%
- Selling and Administrative Expenses 31 31
49% 49%
51,700%
- Research and Development Expense 150 150
4% 4%
250,433%
-201 -201
7% 7%
-334,800%
- Depreciation and Amortization 20 20
2% 2%
32,767%
EBIT (Operating Income) EBIT -221 -221
7% 7%
-367,570%
Net Profit -204 -204
7% 7%
-339,983%

In millions USD.

Don't miss a Thing! We will send you all news about Lyell Immunopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lyell Immunopharma Inc Stock News

Neutral
GlobeNewsWire
21 days ago
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, today announced that an abstract highlighting initial clinical data from the Phase 1-2 study of IMPT-314 in large B-cell lymphoma will be presented...
Neutral
GlobeNewsWire
26 days ago
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) --  Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, announced today that it has completed its acquisition of ImmPACT Bio USA Inc. (“ImmPACT”), a privately-owned clinical-stage c...
Positive
Seeking Alpha
about one month ago
Lyell Immunopharma, Inc.'s financials show reduced losses and efficient cash management, with a strong cash position supporting operations through 2027 despite a challenging biotech environment. The company's innovative CAR T-cell therapies, particularly LYL119 and IMPT-314, target critical oncology challenges with promising early clinical results expected by late 2025. Lyell's acquisition of I...
More Lyell Immunopharma Inc News

Company Profile

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.

Head office United States
CEO Lynn Seely
Employees 224
Founded 2018
Website www.lyell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today